Scientific Publications

Advancing dermatological science.

March 2023 Featured

AAD 2023

Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial: Assessment of Pruritus

May 2024

JAAD

Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial

March 2024

AAD 2024

Patient-Reported Outcomes With Roflumilast Foam 0.3% in Patients With Scalp and Body Psoriasis in the Phase 3 ARRECTOR trial

March 2024

AAD 2024

Roflumilast Foam 0.3% Once Daily in Patients With Seborrheic Dermatitis: Improvement in Patient-Reported Outcomes and Pruritus From a Phase 3 Trial (STRATUM)

October 2023

British Journal of Dermatology

Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study

September 2022

EADV 2022

Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial

September 2022

EADV 2022

Long-term Safety and Efficacy of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a 24–52-week, Open-label Phase 2 Trial

September 2022

EADV 2022

Efficacy and Safety by Race and Ethnicity in a Randomized, Double-blind, Vehicle-Controlled, Phase 2a Study Evaluating Once-Daily Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis

April 2022

AAD 2022

Effect of Roflumilast Foam 0.3% Treatment of Seborrheic Dermatitis on Patient Quality of Life: Results From a Phase 2 Study

September 2021

EADV 2021

Roflumilast Foam 0.3% Improved the Severity and Burden of Itch in Patients with Scalp and Body Psoriasis

September 2021

EADV 2021

Roflumilast Foam 0.3%, Safety and Efficacy in Patients with Seborrheic Dermatitis

April 2021

AAD 2021

Roflumilast Foam, Safety and Efficacy in Patients with Scalp and Body Psoriasis, Ph2b Study

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download